IngredientsAdenine (symbol: A, abbreviation: Ade) is a purine nucleobase that serves as one of the four canonical nitrogenous bases found in both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Adenine is a purine nucleotide base that is found in DNA, RNA, and ATP. Its systematic IUPAC chemical name is 9H-Purin-6-amine, and it is also widely referred to by the synonyms 6-Aminopurine and, historically, Vitamin B4. Adenine's molecular formula is C₅H₅N₅.
Structurally, adenine is a bicyclic aromatic heterocycle. Purines are heterocyclic aromatic organic compounds. As a purine, adenine is comprised of two carbon rings: a pyrimidine ring and an imidazole ring. Adenine is a purine nucleobase that has an amine group linked to the carbon at position 6. It typically appears as a white crystalline powder. Its CAS registry number is 73-24-5.
Adenine forms adenosine, a nucleoside, when attached to ribose, and deoxyadenosine when attached to deoxyribose. It forms adenosine triphosphate (ATP), a nucleoside triphosphate, when three phosphate groups are added to adenosine. Adenosine triphosphate is used in cellular metabolism as one of the basic methods of transferring chemical energy between chemical reactions.
Adenine is a universal constituent of all living cells. Adenine, guanine, hypoxanthine, and xanthine are the primary purine bases in plants and animals. In foods, purines exist as free bases, nucleosides, nucleotides, and nucleic acids in RNA and DNA, with nucleic acids being the predominant form.
Adenine content in foods has been quantified by the USDA and associated researchers. Mean adenine content was highest in organ products. More specifically, mean adenine content (mg/100 g) was highest in organ products (46.1–62.4 mg), while it was lowest in dairy and egg products (2.04 mg), in fruits (0.85 mg), and in sweets (0.7 mg). Examples of high-purine food sources include anchovies, sardines, liver, beef, kidneys, brains, monkfish, dried mackerel, and shrimp. Among alcoholic beverages, regular beer had the highest adenine (1.63 mg/100 mL) among alcoholic beverages reported.
Distribution across food categories is not uniform. Hypoxanthine was the predominant purine base found in meats and seafood, whereas dairy, vegetables, and legumes were primarily composed of adenine and guanine. Some vegetables, such as cauliflower, spinach, and peas, have considerable levels of purines, but do not contribute to elevated uric acid levels, possibly due to digestion and bioavailability factors.
The USDA also analyzed dietary supplements for purine content: a total of 61 U.S. foods and 14 dietary supplements in 5 categories (brewer's yeast, chlorella, spirulina, RNA/DNA complex, royal jelly) were analyzed for four purine bases (adenine, guanine, hypoxanthine, and xanthine) and uric acid. Yeast is a particularly notable dietary source: yeast cells synthesize adenine de novo through the purine biosynthetic pathway, starting from simple precursors (like amino acids and ribose-5-phosphate).
In research and medical settings, adenine is available as a pure crystalline powder, and as a USP-grade reagent. Clinically, its most established use is as an additive in blood banking anticoagulant and preservative solutions (discussed in detail in Section 5). In dietary supplement form, adenine may appear as a constituent in brewer's yeast preparations, RNA/DNA nucleotide complex supplements, and royal jelly products. It is not widely marketed as a standalone isolated supplement in the same fashion as, for example, common vitamins.
The history of adenine as a compound of scientific interest begins in the late nineteenth century. Adenine was first isolated from pancreatic tissue by Albrecht Kossel in 1885, marking a significant milestone in biochemistry. Kossel, a German biochemist who went on to win the Nobel Prize in Physiology or Medicine in 1910 for his work on cell chemistry, identified adenine as one of the nitrogenous constituents of nucleic acids.
In the early decades of the twentieth century, before the full complexity of the vitamin B complex was elucidated, adenine became entangled in the effort to identify all factors essential to animal health. Early studies of chicks and rats that were fed autoclaved cereals without nutritional supplements indicated that these animals exhibited retarded growth and developed general muscular weakness leading to paralysis. Dr. V. Reader isolated a factor from both yeast and liver that alleviated these symptoms, and he later termed the factor vitamin B-4. This vitamin was determined to be adenine, the purine present as a nucleotide base in both DNA and RNA.
A key contribution came from Vera Reader in the late 1920s, who isolated a growth-promoting factor from yeast and liver extracts that alleviated symptoms of B-complex deficiency in rats, initially characterizing it as a second thermolabile water-soluble accessory food factor and later assaying it as vitamin B4 in 1930. Further studies in the 1930s linked this factor to adenine, a purine base, with experiments demonstrating that adenine crystals exhibited B4 activity in rat assays, supporting its role as a growth factor in yeast.
The identification was not without controversy in the scientific literature of the period. A short communication published in Nature in 1933 noted the similarity between adenine hydrochloride and crystals previously isolated by Barnes, O'Brien, and Reader, which were specifically stated to have vitamin B4 activity (10γ per diem per rat), but no claim was made that they were actually vitamin B4.
The provisional designation of adenine as "Vitamin B4" was ultimately overturned. Subsequent investigations indicated that the addition of adenine to the deprived animals' diet did not alleviate the retarded growth and paralysis symptoms. Later, workers found that thiamine (vitamin B-1) cured the symptoms, and it is now generally agreed that adenine does not possess any vitamin properties. In other words, what Reader had originally isolated was most likely a mixture of factors, and the true curative principle was thiamine, not adenine.
In older literature, adenine was sometimes called Vitamin B4, but is no longer considered a vitamin. Due to it being synthesized by the body and not essential to be obtained by diet, it does not meet the definition of vitamin and is no longer part of the Vitamin B complex. Adenine, a purine nucleobase, was designated as Vitamin B4 in early classifications because it was thought to be an essential growth factor, but it is now known as a fundamental component of DNA, RNA, and molecules like ATP, which the body produces de novo.
Despite its removal from vitamin classification, adenine retained scientific importance because of its pivotal roles in cellular biochemistry. Two B vitamins, niacin and riboflavin, bind with adenine to form the essential cofactors nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD), respectively. Its role in energy metabolism and nucleic acid structure was fully established by mid-century, and adenine's pairing with thymine was crucial in Watson and Crick's discovery of the DNA double helix structure in 1953.
Adenine (A), along with cytosine (C), guanine (G), and thymine (T), is one of four chemical bases found in DNA. Within the DNA molecule, adenine bases on one strand create chemical interactions with thymine bases on the opposing strand. A four-base DNA sequence contains the cell's genetic instructions. In DNA, adenine binds to thymine via two hydrogen bonds to assist in stabilizing the nucleic acid structures. In RNA, which is used for protein synthesis, adenine binds to uracil.
In cells, adenine is rare as an independent molecule. It is almost always covalently bound to become a part of a larger biomolecule.
Adenine has a central role in cellular respiration. It is part of adenosine triphosphate, which provides the energy that drives and supports most activities in living cells, such as protein synthesis, muscle contraction, and nerve impulse propagation. In respiration it also participates as part of the cofactors nicotinamide adenine dinucleotide, flavin adenine dinucleotide, and coenzyme A.
In addition to being the major component of nucleic acids, adenine is a critical component of adenosine triphosphate (ATP), which is adenosine with three phosphate groups attached to it. Adenosine triphosphate (ATP) is a high-energy molecule required for cellular metabolism and other biological functions. The energy-rich ATP and the cofactors nicotinamide adenine dinucleotide (NAD), Flavin Adenine Dinucleotide (FAD), and Coenzyme A are involved in a variety of biochemical processes, including cellular respiration.
The human body can produce adenine through two fundamental biosynthetic routes: the de novo synthesis pathway and the salvage pathway. Purine nucleotides are vital for RNA and DNA synthesis, signaling, metabolism, and energy homeostasis. To synthesize purines, cells use two principal routes: the de novo and salvage pathways.
The de novo synthesis pathway uses glutamine, aspartate and glycine to synthesize purine rings de novo, which consumes a total of 6 ATPs. This pathway is finely regulated by various mechanisms, including transcriptional and post-transcriptional regulation, feedback inhibition regulation, multi-enzyme complex assembly processes, and several pro-growth signaling pathways to support cell growth.
The salvage pathway is considerably more energy-efficient. The salvage pathway operates alongside the de novo pathway, by recycling existing nucleobases from the diet or nucleotide catabolism, to produce nucleotides in an energy-efficient manner, consuming only 1 ATP molecule per purine molecule. The salvage synthesis pathway is mainly regulated by two key enzymes, adenine phosphoribosyl transferase (APRT) and hypoxanthine guanine phosphoribosyl transferase (HPRT1). Specifically, the purine salvage pathway restores adenine nucleotide levels via HPRT (hypoxanthine to IMP) and APRT (adenine to AMP).
Traditionally, it is believed that proliferating cells predominantly rely on de novo synthesis, whereas differentiated tissues favor the salvage pathway. Unexpectedly, research has found that adenine and inosine are the most effective circulating precursors for supplying purine nucleotides to tissues and tumors, while hypoxanthine is rapidly catabolized and poorly salvaged in vivo.
Adenine is degraded as follows: adenosine → inosine (via the enzyme purine nucleoside phosphorylase) → hypoxanthine (via the enzyme xanthine oxidase) → xanthine (via the enzyme xanthine oxidase) → uric acid. In humans and other vertebrates, the exogenous purines such as adenine and guanine are degraded in the liver. As a result of purine degradation, uric acid is produced as a waste product. The uric acid is released from the liver into the bloodstream, through which it reaches the kidney. It is then excreted from the body via the urine.
Adenine from catabolism may be salvaged and re-used by the catalytic activity of the enzyme adenine phosphoribosyltransferase.
Beyond its role in ATP, adenine is an essential structural component of the coenzymes NAD⁺ and FAD. Two B vitamins, niacin and riboflavin, bind with adenine to form the essential cofactors nicotinamide adenine dinucleotide (NAD) and flavin adenine dinucleotide (FAD), respectively. These cofactors are critical mediators of oxidation-reduction (redox) reactions throughout the cell, including the electron transport chain during aerobic respiration.
Research in yeast has illuminated the regulatory relationship between adenine levels and NAD⁺ biosynthesis. A co-regulation of purine and pyridine metabolism in response to external adenine has been established through two separable mechanisms. First, adenine depletion promotes transcriptional upregulation of the de novo NAD⁺ biosynthesis genes by a mechanism requiring key purine intermediates. Second, adenine supplementation favors the pyridine salvage route resulting in an ATP-dependent increase of intracellular NAD⁺.
Adenine is foundational to cellular biology: it is a structural component of DNA and RNA, underpinning genetic information storage and protein synthesis. Through its role in ATP, it drives virtually all energy-requiring cellular processes. Through its role in NAD and FAD, it mediates redox biochemistry and metabolic signaling across all tissue types.
One of the most clinically documented uses of exogenous adenine is in the preservation of red blood cells (erythrocytes) for transfusion medicine. Adenine is an approved additive to citrate-phosphate-dextrose anticoagulant for whole blood collection and extends the storage life of red blood cells. The mechanism relates to ATP maintenance: red blood cell viability, as monitored by ATP concentrations, was maintained by use of adenine and extra glucose.
The kidneys are the primary site of adenine-related pathology under conditions of abnormal purine metabolism. In individuals with the inherited enzyme defect known as APRT deficiency, excess adenine accumulates and is shunted toward a harmful metabolic byproduct (see Section 6.2). Additionally, dietary purine excess, including excess adenine intake, increases circulating uric acid levels, with consequences for renal function. Purine intake has shown the biggest dietary impact on uric acid.
The brain is highly dependent on adenine nucleotide (ATP) homeostasis. The brain, like the heart, relies largely upon the purine salvage pathway for the restoration of adenine nucleotides, as de novo synthesis is slow and not increased after metabolic stress. This has led to research interest in adenine as a potential component of neuroprotective strategies, particularly following ischemic or traumatic brain injury (see Section 5.2).
Elevated uric acid resulting from excess purine catabolism — including catabolism of dietary adenine — is the primary etiological factor in gout, a painful form of inflammatory arthritis. Hyperuricemia, defined as high levels of blood uric acid, is the major etiological factor of gout. Studies highlighting the pathogenic mechanisms of uric acid point to an inflammatory response as the primary mechanism for inducing gout and possibly contributing to uric acid's vascular effects. Monosodium urate (MSU) crystals induce an inflammatory reaction, which are recognized by Toll-like receptors (TLRs). These TLRs then activate the NALP3 inflammasome.
Evidence Strength: Strong (established clinical practice).
The use of adenine in blood preservation solutions is the most clinically validated application of exogenous adenine and represents its only widely accepted medical use. Supplementation of the ACD-preservative with small amounts of adenine (0.5 µM per ml, amounting to 37 mg of the base or 56 mg of adenine sulfate per 550 ml unit of blood) preserved satisfactory viability (post-transfusion survival greater than 70 per cent) of stored human red cells for 5 to 6 weeks. This foundational finding was published in 1962 in Blood, the journal of the American Society of Hematology.
Subsequent research confirmed and refined these findings. A multi-institutional study found that red blood cells from eight units stored as concentrates for 28 days showed a mean survival of 83.97 ± 6.10 per cent, and modified CPD with adenine as formulated offers an improved anticoagulant for blood banking by extending the permissible red blood cell storage period. Later work on additive solution systems containing adenine showed further improvements: the use of CPD-collected red blood cells with an OAS containing adenine, glucose, and ascorbate-2-phosphate, or CPD-adenine collected red blood cells with an OAS containing ascorbate-2-phosphate, demonstrates the potential to store red blood cells at least 42 days and to maintain red blood cell 2,3-DPG.
Research using the saline-adenine-glucose-mannitol (SAGM) additive solution showed that after removal of plasma and buffy coat, the red cells were suspended in SAGM medium. After 42-day refrigerator storage, the total adenine nucleotide concentration remained the same as the initial concentration in the red cells, whereas ATP levels had decreased to 61 percent of the initial value.
A detailed metabolomics study of adenine metabolism in stored RBCs found that adenine is one of the main substrates used by RBCs, but the metabolic shift observed during storage is not caused by an absence of adenine later in storage. The rate of adenine consumption strongly correlated with duration of storage but not with the amount of adenine present in the additive solution.
Evidence Strength: Preliminary (preclinical and ex vivo; no completed human clinical trials identified).
Research published in Neurochemical Research has investigated adenine's role in restoring ATP levels in the context of brain injury. The restoration of cellular ATP in brain slices to in vivo values is possible with a simple combination of D-ribose and adenine (RibAde), two substrates for ATP synthesis. Restoration of ATP in slices to physiological levels has implications for synaptic transmission and plasticity, whilst in the injured brain in vivo RibAde shows encouraging positive results.
The rationale for targeting adenine specifically in brain injury relates to the organ's reliance on purine salvage: the brain, like the heart, relies largely upon the purine salvage pathway for the restoration of adenine nucleotides, as de novo synthesis is slow and not increased after metabolic stress. Given that ribose, adenine, and a third compound, allopurinol, are all separately in use in man, their combined application after acute brain injury, in accelerating ATP synthesis and increasing the reservoir of the neuroprotective metabolite, adenosine, may help reduce the morbidity associated with stroke and traumatic brain injury.
Mechanistically, purine salvage restores adenine nucleotide levels directly via APRT (adenine phosphoribosyltransferase; adenine to AMP) and indirectly via HPRT. This reaction requires PRPP (phosphoribosyl pyrophosphate), which is produced from the ribose-5-phosphate that emerges from the pentose phosphate pathway. However, this body of research remains at a preclinical stage. No large-scale human clinical trials with adenine as a standalone neuroprotective intervention have been identified in the peer-reviewed literature. This represents a promising but unproven area.
Evidence Strength: Preclinical (animal and cell studies); no therapeutic recommendations for supplementation.
Research published in Cell (2024) provided novel findings on how adenine is used by both normal tissues and tumors. Adenine and inosine are the most effective circulating precursors for supplying purine nucleotides to tissues and tumors, while hypoxanthine is rapidly catabolized and poorly salvaged in vivo. Importantly, feeding mice nucleotides accelerates tumor growth, while inhibiting purine salvage slows down tumor progression, revealing a crucial role of the salvage pathway in tumor metabolism. These findings underscore the complexity of adenine's role and suggest that supplemental adenine could theoretically support both normal and malignant cells; this has implications for the prudence of high-dose purine supplementation in certain clinical contexts.
Evidence Strength: Moderate-to-strong epidemiological and mechanistic evidence for dietary purine intake and uric acid elevation.
Unlike most supplement areas where the question is whether more of a compound is beneficial, in the case of adenine, substantial evidence supports caution about excess intake. Foods particularly rich in hypoxanthine, adenine, and guanine lead to higher blood levels of uric acid. Japanese Guidelines for the Management of Hyperuricemia and Gout recommend the daily intake of dietary purines to be less than 400 mg to prevent hyperuricemia and gout development.
The pathophysiology of elevated uric acid — produced as the terminal metabolite of adenine catabolism — is well-characterized. When the pro-inflammatory effects of urate exceed the anti-inflammatory effect, especially as its dissolution exceeds the limit (>6.8 mg/dL), gout occurs. When uric acid accumulates in the kidneys and joints, it can lead to diseases such as uric acid nephropathy and gouty arthritis, eventually leading to renal failure, joint deformity, and even death. A number of epidemiological reports have increasingly linked hyperuricemia with cardiovascular and neurological diseases.
There is no established Recommended Dietary Allowance (RDA) or Adequate Intake (AI) for adenine itself, as it does not hold dietary essential status.
The most precisely reported clinical dosage for adenine is in its blood banking application. Supplementation of the ACD-preservative with small amounts of adenine — 0.5 µM per ml, amounting to 37 mg of the base or 56 mg of adenine sulfate per 550 ml unit of blood — preserved satisfactory viability of stored human red cells for 5 to 6 weeks.
In the early animal studies investigating the putative role of adenine as Vitamin B4, adenine was administered at the rate of 20 mg per rat per day. These animal dosages are noted for historical completeness and have no established extrapolation to human dietary supplementation.
From a dietary management perspective relevant to adenine as a dietary constituent, Japanese Guidelines for the Management of Hyperuricemia and Gout recommend the daily intake of dietary purines to be less than 400 mg to prevent hyperuricemia and gout development. Adenine is one of the four main purine bases assessed in total dietary purine calculations alongside guanine, hypoxanthine, and xanthine.
Adenine is a normal endogenous constituent of all human cells and is present in all foods containing nucleic acids. At levels present in ordinary dietary intake, it is metabolized through well-characterized pathways. However, excess exogenous adenine intake carries specific, documented risks.
The most significant safety consideration associated with adenine metabolism is APRT deficiency, a genetic disorder that profoundly alters how adenine is handled in the body. Adenine phosphoribosyltransferase (APRT) deficiency is a rare autosomal recessive disorder which causes high urinary 2,8-dihydroxyadenine (2,8-DHA) excretion, resulting in urolithiasis and crystal nephropathy. It is caused by mutations in the APRT gene.
The mechanism of harm in APRT deficiency is as follows: in the absence of APRT, adenine is metabolized by xanthine oxidase to 2,8-dihydroxyadenine via the intermediate 8-hydroxyadenine. 2,8-Dihydroxyadenine is excreted by the kidneys and is insoluble in urine at any range of physiological pH, resulting in 2,8-dihydroxyadenine crystalluria and urolithiasis.
The clinical consequences can be severe. APRT deficiency is characterized by excessive production and renal excretion of 2,8-dihydroxyadenine (DHA), which leads to kidney stone formation and crystal-induced kidney damage (i.e., DHA crystal nephropathy) causing acute kidney injury episodes and progressive chronic kidney disease (CKD). Kidney stones, the most common clinical manifestation of APRT deficiency, can occur at any age; in at least 50% of affected persons symptoms do not occur until adulthood. If adequate treatment is not provided, approximately 20%–25% of affected individuals develop end-stage renal disease (ESRD), usually in adult life.
The condition is frequently misdiagnosed. Even though it is an inherited kidney stone disease, the varied clinical presentations, even within a family with the same underlying genetic variants, can lead to delayed diagnosis, with some only being recognized in adulthood and even following a kidney transplant. First presentations include symptoms of reddish-brown diaper stains, urinary tract infections, urolithiasis, acute kidney injury from obstructive uropathy and/or intratubular 2,8-DHA crystallization, or kidney failure.
An early diagnosis and treatment with xanthine oxidoreductase inhibitors (XORi) can preserve kidney function and/or prevent progressive kidney injury and kidney failure. From a dietary standpoint, early recognition of the disease, institution of xanthine analog therapy to block the formation of 2,8-dihydroxyadenine, high fluid intake, and low purine diet prevent CKD.
In individuals with undiagnosed APRT deficiency, the introduction of high-dose adenine supplementation could theoretically exacerbate crystal nephropathy. This represents a specific, non-hypothetical risk backed by substantial case literature, including transplant failure documented in patients with unrecognized APRT deficiency. The disease is most often misdiagnosed and can recur in the renal allograft. In one series of nine patients with recurrent 2,8-DHA crystalline nephropathy, in all of whom the diagnosis had been missed prior to renal transplantation, the diagnosis was established at a median of 5 (range 1.5–312) weeks following the transplant procedure.
For individuals without APRT deficiency, the primary safety consideration associated with excessive dietary adenine intake is the contribution to serum uric acid levels and associated conditions. Foods particularly rich in hypoxanthine, adenine, and guanine lead to higher blood levels of uric acid. Gouty nephropathy, also known as uric acid nephropathy, is a series of kidney disorders caused by an increase in uric acid in the human serum, which accumulates in the renal tubules and interstitium over a long period of time.
Among individuals with hyperuricemia, it significantly elevates the risk of developing conditions like gout, chronic kidney disease, hypertension, cardiovascular disease, and even mortality.
Several dietary supplement categories are known to contain significant quantities of adenine and other purines. Brewer's yeast, chlorella, spirulina, RNA/DNA complex supplements, and royal jelly were identified by USDA analysis as containing measurable purine content, including adenine. Individuals with gout, hyperuricemia, or renal impairment who consume these products in large amounts may be increasing their purine load. Purine data in published literature were limited in scope, food descriptions, and quality, which complicates precise quantification of adenine content in commercially available supplements.
As noted above, preclinical research found that feeding mice nucleotides accelerates tumor growth, while inhibiting purine salvage slows down tumor progression. This finding, from a 2024 study published in Cell, suggests a theoretical concern that high-dose nucleobase supplementation could support proliferating cell populations. This has not been studied in humans in the context of cancer risk, and no causal clinical data are available; however, it is a mechanistic consideration noted in the current scientific literature.
A study of adenine's effects on platelet storage found that in vitro methods demonstrated that although hypotonic shock response and aggregation were decreased, these effects were reversed following separation and resuspension in fresh adenine-free plasma. Serotonin uptake and release were not affected by adenine; however, malonaldehyde formation was slightly enhanced. Glucose, pH, and pO₂ levels were lower, while lactate levels were slightly higher than in platelets stored without adenine. These effects were observed in the context of in vitro platelet storage, not in vivo supplementation.
Health conditions that Adenine may help support.
Body systems that Adenine may help support.
Go back